140 related articles for article (PubMed ID: 26589407)
1. Ensembling and filtering: an effective and rapid in silico multitarget drug-design strategy to identify RIPK1 and RIPK3 inhibitors.
Fayaz SM; Rajanikant GK
J Mol Model; 2015 Dec; 21(12):314. PubMed ID: 26589407
[TBL] [Abstract][Full Text] [Related]
2. Ensemble pharmacophore meets ensemble docking: a novel screening strategy for the identification of RIPK1 inhibitors.
Fayaz SM; Rajanikant GK
J Comput Aided Mol Des; 2014 Jul; 28(7):779-94. PubMed ID: 24980648
[TBL] [Abstract][Full Text] [Related]
3. Novel RIPK3 inhibitors discovered through a structure-based approach exert post-ischemic neuroprotection.
Fayaz SM; Suvanish Kumar VS; Davis CK; Rajanikant GK
Mol Divers; 2016 Aug; 20(3):719-28. PubMed ID: 26873246
[TBL] [Abstract][Full Text] [Related]
4.
Zhang H; Xu L; Qin X; Chen X; Cong H; Hu L; Chen L; Miao Z; Zhang W; Cai Z; Zhuang C
J Med Chem; 2019 Jul; 62(14):6665-6681. PubMed ID: 31095385
[TBL] [Abstract][Full Text] [Related]
5. Structure guided design of potent and selective ponatinib-based hybrid inhibitors for RIPK1.
Najjar M; Suebsuwong C; Ray SS; Thapa RJ; Maki JL; Nogusa S; Shah S; Saleh D; Gough PJ; Bertin J; Yuan J; Balachandran S; Cuny GD; Degterev A
Cell Rep; 2015 Mar; 10(11):1850-60. PubMed ID: 25801024
[TBL] [Abstract][Full Text] [Related]
6. RIPK1 can function as an inhibitor rather than an initiator of RIPK3-dependent necroptosis.
Kearney CJ; Cullen SP; Clancy D; Martin SJ
FEBS J; 2014 Nov; 281(21):4921-34. PubMed ID: 25195660
[TBL] [Abstract][Full Text] [Related]
7. Ring closure strategy leads to potent RIPK3 inhibitors.
Wu S; Xu C; Xia K; Lin Y; Tian S; Ma H; Ji Y; Zhu F; He S; Zhang X
Eur J Med Chem; 2021 May; 217():113327. PubMed ID: 33730678
[TBL] [Abstract][Full Text] [Related]
8. Small-Molecule Inhibitors of Necroptosis: Current Status and Perspectives.
Zhuang C; Chen F
J Med Chem; 2020 Feb; 63(4):1490-1510. PubMed ID: 31622096
[TBL] [Abstract][Full Text] [Related]
9. RIPK1 inhibits ZBP1-driven necroptosis during development.
Newton K; Wickliffe KE; Maltzman A; Dugger DL; Strasser A; Pham VC; Lill JR; Roose-Girma M; Warming S; Solon M; Ngu H; Webster JD; Dixit VM
Nature; 2016 Dec; 540(7631):129-133. PubMed ID: 27819682
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, and evaluation of potent RIPK1 inhibitors with in vivo anti-inflammatory activity.
Li Z; Hao Y; Yang C; Yang Q; Wu S; Ma H; Tian S; Lu H; Wang J; Yang T; He S; Zhang X
Eur J Med Chem; 2022 Jan; 228():114036. PubMed ID: 34906762
[TBL] [Abstract][Full Text] [Related]
11. Critical contribution of oxidative stress to TNFα-induced necroptosis downstream of RIPK1 activation.
Shindo R; Kakehashi H; Okumura K; Kumagai Y; Nakano H
Biochem Biophys Res Commun; 2013 Jun; 436(2):212-6. PubMed ID: 23727581
[TBL] [Abstract][Full Text] [Related]
12. Activity of protein kinase RIPK3 determines whether cells die by necroptosis or apoptosis.
Newton K; Dugger DL; Wickliffe KE; Kapoor N; de Almagro MC; Vucic D; Komuves L; Ferrando RE; French DM; Webster J; Roose-Girma M; Warming S; Dixit VM
Science; 2014 Mar; 343(6177):1357-60. PubMed ID: 24557836
[TBL] [Abstract][Full Text] [Related]
13. RIPK1 and RIPK3: critical regulators of inflammation and cell death.
Newton K
Trends Cell Biol; 2015 Jun; 25(6):347-53. PubMed ID: 25662614
[TBL] [Abstract][Full Text] [Related]
14. 24(S)-Hydroxycholesterol induces RIPK1-dependent but MLKL-independent cell death in the absence of caspase-8.
Vo DK; Urano Y; Takabe W; Saito Y; Noguchi N
Steroids; 2015 Jul; 99(Pt B):230-7. PubMed ID: 25697054
[TBL] [Abstract][Full Text] [Related]
15. Discovery of LRRK2 inhibitors using sequential in silico joint pharmacophore space (JPS) and ensemble docking.
Lang CA; Ray SS; Liu M; Singh AK; Cuny GD
Bioorg Med Chem Lett; 2015 Jul; 25(13):2713-9. PubMed ID: 25998502
[TBL] [Abstract][Full Text] [Related]
16. SnapShot: Necroptosis.
Zhou W; Yuan J
Cell; 2014 Jul; 158(2):464-464.e1. PubMed ID: 25036639
[TBL] [Abstract][Full Text] [Related]
17. Discovery of simplified benzazole fragments derived from the marine benzosceptrin B as necroptosis inhibitors involving the receptor interacting protein Kinase-1.
Benchekroun M; Ermolenko L; Tran MQ; Vagneux A; Nedev H; Delehouzé C; Souab M; Baratte B; Josselin B; Iorga BI; Ruchaud S; Bach S; Al-Mourabit A
Eur J Med Chem; 2020 Sep; 201():112337. PubMed ID: 32659605
[TBL] [Abstract][Full Text] [Related]
18. Necroptosis and Inflammation.
Newton K; Manning G
Annu Rev Biochem; 2016 Jun; 85():743-63. PubMed ID: 26865533
[TBL] [Abstract][Full Text] [Related]
19. Effective virtual screening strategy focusing on the identification of novel Bruton's tyrosine kinase inhibitors.
Xiao J; Zhang S; Luo M; Zou Y; Zhang Y; Lai Y
J Mol Graph Model; 2015 Jul; 60():142-54. PubMed ID: 26043662
[TBL] [Abstract][Full Text] [Related]
20. Pharmacophore and molecular dynamics based activity profiling of natural products for kinases involved in lung cancer.
Singh PK; Silakari O
J Mol Model; 2018 Oct; 24(11):318. PubMed ID: 30343450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
